Loading organizations...
DNAtrix develops oncolytic virus immunotherapies, engineering modified viruses that selectively target and destroy cancer cells. The company's core technology leverages a proprietary adenovirus platform to create virus-driven treatments for aggressive forms of cancer. Its lead product candidate, DNX-2401, is a conditionally replicative oncolytic adenovirus primarily designed to treat high-grade malignant gliomas, with another candidate, DNX-2440, also in clinical development.
The company was founded in 2005 by a team of physicians and scientists: Juan Fueyo, M.D., Candelaria Gomez-Manzano, M.D., and Charles Conrad. Their collective expertise and foundational insight centered on harnessing the therapeutic potential of viruses to combat refractory cancers. Based in Houston, Texas, DNAtrix was formed to translate this scientific understanding into clinical applications, expanding its capabilities through strategic corporate development including a merger with VectorLogics.
DNAtrix’s therapies are developed for patients with aggressive cancers, particularly those with limited treatment options such as high-grade malignant gliomas. The company’s long-term vision is to establish its oncolytic virus platform as a cornerstone of cancer therapy, continuously advancing its pipeline to provide novel and effective immunotherapeutic solutions that improve patient outcomes.
DNAtriX has raised $36.3M across 4 funding rounds.
DNAtriX has raised $36.3M in total across 4 funding rounds.
DNAtriX has raised $36.3M in total across 4 funding rounds.
DNAtriX's investors include Reenie McCarthy, Mercury Fund, Targeted Technology Fund, Cancer Prevention and Research Institute of Texas.
DNAtrix is a Houston, Texas-based biotech company developing oncolytic virus immunotherapies to treat aggressive cancers, particularly glioblastoma.[1][2][3] Its lead product, DNX-2401, is an engineered adenovirus derived from the common cold virus that selectively targets and kills cancer cells while sparing healthy ones; it is advancing to a global Phase 3 trial for recurrent glioblastoma and holds FDA Fast Track and Rare Pediatric Disease designations for diffuse intrinsic pontine glioma.[1][2] The company also pursues candidates like DNX-2440 (Phase 1 for colorectal cancer with liver metastases) and others for ovarian, pancreatic, brain metastases, and solid tumors, serving patients with hard-to-treat cancers where traditional therapies fail.[1][2] With estimated revenue of $6.2 million and investors including Morningside Ventures and Mercury Fund, DNAtrix shows steady clinical momentum in oncolytic virotherapy.[2]
Founded in 2005 and headquartered in Houston, Texas, DNAtrix emerged from research into engineered adenoviruses for cancer treatment.[3] The company's platform builds on modifying common cold viruses to create tumor-selective killers, with early focus on glioblastoma—an incurable brain tumor driving the development of DNX-2401.[1][2] Key milestones include initiating clinical trials starting in 2018 (e.g., Phase 1 studies) and recent advancements like FDA designations for pediatric glioma, positioning it for pivotal Phase 3 testing.[1][2] While specific founders are not detailed in available data, the firm's longevity reflects sustained progress from preclinical innovation to multi-indication pipelines.[1][3]
DNAtrix stands out in biotech through its specialized oncolytic virus platform. Key strengths include:
DNAtrix rides the oncolytic virotherapy wave, a growing segment of immuno-oncology where engineered viruses harness the immune system against tumors, complementing checkpoint inhibitors and CAR-T therapies.[1][2] Timing aligns with rising demand for precision treatments amid glioblastoma's dismal prognosis (median survival ~15 months) and failures of standard chemo/radiation.[1] Favorable market forces include FDA incentives for rare pediatric diseases, surging biotech investment in viral vectors (post-COVID mRNA momentum), and partnerships potential in a $100B+ oncology market.[2] By pioneering adenovirus-based killers, DNAtrix influences the ecosystem, validating virotherapy for "cold" tumors like brain cancers and paving paths for combo regimens with big pharma.[1][2]
DNAtrix is primed for Phase 3 readouts on DNX-2401, potentially yielding first approvals in glioblastoma by late 2020s if data succeeds, alongside pipeline expansions into high-burden cancers.[1][2] Trends like AI-optimized virus design, immune combo trials, and global orphan drug demand will propel growth, though execution risks in late-stage oncology persist. Its influence could amplify as a virotherapy leader, drawing acquisitions or alliances—echoing how targeted biologics reshaped cancer care, much like its cold-virus roots revolutionized tumor targeting.[1][2]
DNAtriX has raised $36.3M across 4 funding rounds. Most recently, it raised $20.0M Series B in October 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2014 | $20.0M Series B | Reenie McCarthy | Mercury Fund, Targeted Technology Fund |
| Feb 24, 2014 | $10.8M Grant | Cancer Prevention and Research Institute of Texas | |
| Jan 1, 2012 | $5.0M Seed | Mercury Fund | |
| Aug 1, 2008 | $480K Seed | Mercury Fund |